Oxehealth’s vision based patient monitoring software gets FDA Clearance

Oxehealth Vital Signs software

Oxehealth Vital Signs platform has been cleared by FDA as a part of a new DeNovo filing that was spotted today. The software provides optical camera-based contactless measurement of pulse rate, heart rate, respiratory rate and more.

Made by a UK-based startup with strong ties to NHS and the Euopean health community, Oxehealth Limited, the remote monitoring platform is unique in that it does not require a wearable sensor to be used on the patient’s body. Instead, the platform uses camera and sensors to detect and read important parameters such as pulse rate and respiratory rate using computer vision.

Related Reading:

How does Oxehealth monitoring platform work

When your heart beats, your skin flushes red. The human eye cannot see these “micro blushes” but Oxehealth’s optical sensor can, using infrared light and our proprietary signal processing techniques. Our software counts the micro blushes to calculate a pulse rate.

The scientific breakthrough is the platform’s ability to use PPG to detect pulse rate from several meters away.

Oxehealth’s system calculates breathing rate by counting the movements of the body created by chest and diaphragm breathing, just as a nurse would if they were observing the patient with a stopwatch.

The system is somewhat similar to a feature that was unveiled in the latest Google’s Nest hub. The ‘Sleep Sensing’ Google feature allows for sleep tracking via motion detector.

Additional Patient monitoring features 

Oxehealth’s Vital Signs platform can not only track the patient’s vitals, but also provide additional motion based monitoring service such as sleep monitoring, overnight activity monitoring and out of room alerts and more.

 The platform consists of a secure optical sensor that is installed in a patient’s room. The sensor continuously tracks and obtains contact-free readings from the patient, no matter where they are in the room. Information and alerts are automatically provided to health care facilities.

The company’s Vital Signs module is a class IIa medical device cleared in Europe. It is not available for sale, demonstration or trial use in any country outside the EU or UK.Oxehealth Vital Signs FDA Clearance

Now with the latest DeNovo clearance, this contactless monitoring platform could soon find its way in US health facilities. 

Oxehealth secured financial commitments totaling £10m this month, which will be delivered in two rounds across 2021 and 2022. The rounds have been underwritten by existing shareholders and will be used to fund the commercial expansion of Oxevision, a vision-based patient monitoring and management platform.

I am a technologist with years of experience with Apple and wearOS products and have a Bachelor’s degree in Computer Science. In my day job, I advise fortune 500 companies with their digital transformation strategies and also consult with numerous digital health startups in an advisory capacity. I'm VERY interested in exploring the digital health&fitness-tech evolution and keep a close eye on patents, FDA approvals, strategic partnerships and developments happening in the wearables and digital health sector. When I'm not writing or presenting, I run with my Apple Watch or Fossil Gen 5 LTE and keep a close eye on my HRV and other recovery metrics.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.